Barclays analyst Gena Wang lowered the firm’s price target on Bluebird Bio (BLUE) to $2 from $4 and keeps an Overweight rating on the shares. The company reported a Q3 revenue miss due to the timing of infusions, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE: